The Antithrombotic Properties of Coumarin Drugs

Article1 January 1961THE ANTITHROMBOTIC PROPERTIES OF COUMARIN DRUGSJOHN C. HOAK, M.D., WILLIAM E. CONNOR, M.D., EMORY D. WARNER, M.D., JOHN R. CARTER, M.D.JOHN C. HOAK, M.D., WILLIAM E. CONNOR, M.D., EMORY D. WARNER, M.D., JOHN R. CARTER, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-54-1-73 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptINTRODUCTIONIn recent years, coumarin drugs have played an important role in the treatment of thrombo-embolic disease. Despite the widespread use of these drugs, the exact mechanism by which they inhibit thrombosis is unknown.Since anticoagulant activity, as measured by in vitro methods, is not necessarily synonymous with antithrombotic activity, a laboratory test which approximates in vivo clotting conditions would be extremely useful. Blood coagulates when it is placed in a glass tube because the "glass or contact factor" is activated and initiates clotting.1Blood normally remains fluid within the blood vessels and clots more slowly in a siliconized tube...Bibliography1. Margolis J: The role of Hageman factor in plasma/surface reactions, in Hemophilia and Other Hemorrhagic States, pp. 208-228, Brinkhous, K. M., Editor, University of North Carolina Press, Chapel Hill, 1959. Google Scholar2. HubbardLucas DGL: Ionic charges of glass surfaces and other materials, and their possible role in the coagulation of blood, J. Appl. Physiol. 15: 265, 1960. CrossrefMedlineGoogle Scholar3. MoloneyMurphyHarrington WCASWJ: Prolongation of the coagulation of whole blood by dicumarol in man, Amer. J. Med. 5: 40, 1948. CrossrefMedlineGoogle Scholar4. MarguliesBarker HNW: The coagulation time of blood in silicone tubes in patients receiving dicumarol, Amer. J. Med. Sci. 218: 52, 1949. CrossrefMedlineGoogle Scholar5. WalkerHunke WRB: Action of coumarin anticoagulants on a possible new serum clotting factor, Nature 173: 1192, 1954. CrossrefMedlineGoogle Scholar6. SiseKimbalAdamis HSDMD: Plasma thromboplastin component (PTC) deficiency produced by prolonged administration of prothrombopenic anticoagulants, Proc. Soc. Exp. Biol. Med. 89: 81, 1955. CrossrefMedlineGoogle Scholar7. Naeye L: Plasma thromboplastin component: influence of coumarin compounds and vitamin K on its activity in serum. Proc. Soc. Exp. Biol. Med. 91: 101, 1956. CrossrefMedlineGoogle Scholar8. JohnsonSeegers SAWH: The reduction of autoprothrombin II; activity with dicumarol, Circulat. Res. 4: 182, 1956. CrossrefMedlineGoogle Scholar9. McElfreshOage AEA: The effect of coumarin drugs upon plasma thromboplastin component, J. Lab. Clin. Med. 49: 753, 1957. MedlineGoogle Scholar10. HougieBarrowGraham CEMJB: Stuart clotting defect, I. Segregation of an hereditary hemorrhagic state from the heterogeneous group heretofore called "stable factor (SPCA, Proconvertin, Factor VII) deficiency," J. Clin. Invest. 36: 485, 1957. CrossrefMedlineGoogle Scholar11. Douglas AS: Mode of action of coumarin drugs, Brit. Med. Bull. 11: 39, 1955. CrossrefMedlineGoogle Scholar12. TelferDensonWright TDDWDR: A new coagulation defect, Brit. J. Haemat. 2: 308, 1956. CrossrefMedlineGoogle Scholar13. SiseLavelleAdamisBecker HSSMDR: Relation of hemorrhage and thrombosis to prothrombin during treatment with coumarin-type anticoagulants, New Engl. J. Med. 259: 266, 1958. CrossrefMedlineGoogle Scholar14. LeeWhite RIPD: A clinical study of the coagulation time of blood, Amer. J. Med. Sci. 145: 495, 1913. CrossrefGoogle Scholar15. ConnorCarter WEJR: Influence of soybean phosphatide on blood coagulation and its use in the thromboplastin generation test, Proc. Soc. Exp. Biol. Med. 97: 38, 1958. CrossrefMedlineGoogle Scholar16. BiggsDouglas RAS: Thromboplastin generation test, J. Clin. Path. 6: 23, 1953. CrossrefMedlineGoogle Scholar17. Quick AJ: On the quantitative estimation of prothrombin, Amer. J. Clin. Path. 19: 560, 1945. CrossrefGoogle Scholar18. WareSeegers AGWH: Two-stage procedure for the quantitative determination of prothrombin concentrations, Amer. J. Clin. Path. 19: 471, 1949. CrossrefMedlineGoogle Scholar19. CarterWarner JRED: Quantitative estimation of plasma accelerator globulin, Proc. Soc. Exp. Biol. Med. 97: 38, 1958. MedlineGoogle Scholar20. WesslerMorris SLE: Studies in intravascular coagulation. IV. The effect of heparin and dicumarol on serum-induced venous thrombosis, Circulation 12: 553, 1955. CrossrefMedlineGoogle Scholar21. WesslerBallonKatz SJDJH: Studies in intravascular coagulation. V. A distinction between the anticoagulant and antithrombotic effects of dicumarol, New Engl. J. Med. 256: 1223, 1957. CrossrefMedlineGoogle Scholar22. WesslerReiner SS: The role of human coagulation factors in serum-induced thrombosis, J. Clin. Invest. 39: 262, 1960. CrossrefMedlineGoogle Scholar23. ReinerWesslerDeykin SMSD: Observations on the nature of thrombosis-inducing activity of mammalian serum, Fed. Proc. 19: 62, 1960. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Iowa City, Iowa*Received for publication June 27, 1960.Presented at the Forty-first Annual Session of The American College of Physicians, San Francisco, California, April 5, 1960.From the Cardiovascular Research Laboratories, Department of Internal Medicine and Department of Pathology, State University of Iowa College of Medicine, Iowa City, Iowa.†This work was supported by research grants from the American and Iowa Heart Associations and the National Institutes of Health.Requests for reprints should be addressed to William E. Connor, M.D., Department of Internal Medicine, University Hospitals, Iowa City, Iowa. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCoumarins as Modulators of the Keap1/Nrf2/ARE Signaling Pathway6 Oral anticoagulants for the treatment of venous thromboembolismAn audit of anticoagulant guidelines: the relative influence of education, presentation and complexity of guidelines on complianceHeparin for 5 Days as Compared with 10 Days in the Initial Treatment of Proximal Venous ThrombosisDetermination of vitamin K sensitive coagulation factors in plasma. Studies on three methods using synthetic chromogenic substratesAnticoagulantsDeep Vein Thrombosis and Pulmonary Embolism in Congenital Factor VII DeficiencyWarfarin TherapyThe Coagulant and Thrombogenic Properties of Human AtheromaAn overview of anticoagulant therapy for coronary artery diseaseStudies on blood coagulation and thrombosis and on the action of heparin in ischemic heart disease∗"Purple Toes": an Uncommon Sequela of Oral Coumarin Drug TherapyWALTER FEDER, M.D., ROBERT AUERBACH, M.D.Fibrinolysin for ThrombosisMore Virus Inhibitors 1 January 1961Volume 54, Issue 1Page: 73-81KeywordsBlood plasmaBlood vesselsCardiology and cardiovascular diseasesCoumarinsDrugsHeartLaboratory testsResearch grantsResearch laboratoriesThrombosis ePublished: 1 December 2008 Issue Published: 1 January 1961 PDF downloadLoading ...